Objective: To probe into the efficacy of procaterol combined with montelukast in the treatment of bronchial asthma in children and its effects on chemokine-like factor-1 (CKLF-1)

eosinophil cationic protein (ECP)

interleukin-12 (IL-12)

interleukin-13 (IL-13) and lung function. Methods: Totally 94 children with bronchial asthma admitted into our hospital from Aug. 2017 to Apr. 2019 were extracted to be divided into the control group and the observation group via the random number table

with 47 cases in each group. Both groups received conventional treatment such as anti-inflammatory

asthma relieving and bronchiectasia treatment. The control group was given montelukast sodium tablets

while the observation group received procaterol on the basis of the control group. The clinical efficacy of two groups were compared. The levels of CKLF-1

ECP

IL-12

IL-13 and changes of lung function in two groups were analyzed before and after treatment. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the observation group (8.51%) and the control group (4.26%

P>0.05). Before treatment

there was no significant difference in the levels of CKLF-1

ECP

IL-12

IL-13 and lung function indexes between two groups (P>0.05). After treatment

the levels of IL-12

forced expiratory volume in 1 second (FEV1)

FEV1/FVC

peak expiratory flow (PEF) and peak expiratory flow rate (PEFR) in the observation group were higher than those in the control group

while the levels of CKLF-1

ECP and IL-13 were lower than those in the control group (P<0.05). Conclusion: Procatechol combined with montelukast in the treatment of children with bronchial asthma can improve the lung function

regulate the expression levels of CKLF-1

ECP

IL-12 and IL-13

and improve the clinical efficacy without increasing adverse drug reactions.